ECM
CBMG

Element Capital Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Element Capital Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-21,160
Closed -$225K – 184
2017
Q3 		$225K Sell
21,160
-25,196
-54% -$238K 0.09% 35
2017
Q2 		$406K Buy
+46,356
New +$408K 0.08% 44

Other funds holding CBMG

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Element Capital Management's CBMG Position: Q4 2017 in Review

Element Capital Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2017, closing a stake of 21,160 shares — an estimated $225K sold.

Element Capital Management first reported a position in CBMG in Q2 2017 and held it in 2 quarters. The position peaked at $406K in Q2 2017. 17 funds tracked by Wall St. Rank hold CBMG as of Q4 2017.

  • Element Capital Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2017 after selling out during the quarter.
  • Element Capital Management sold 21,160 Cellular Biomedicine Group, Inc. shares in Q4 2017, an estimated $225K.
  • Element Capital Management first reported a position in Cellular Biomedicine Group, Inc. in Q2 2017 and held it in 2 quarters.
  • Element Capital Management's Cellular Biomedicine Group, Inc. position peaked at $406K in Q2 2017.
  • 17 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2017.

Based on Element Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.